Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2020 16:05 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS SECOND YEAR OF PHASE 3 CARDINAL TRIAL CONTINUING AS PLANNED ENROLLMENT OF NEW...
February 19, 2020 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs

PLANO, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial...
February 12, 2020 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020

PLANO, Texas, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and...
November 18, 2019 11:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its...
November 13, 2019 19:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an...
November 12, 2019 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to...
November 12, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results...
November 11, 2019 16:02 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome

ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT ACHIEVED KEY SECONDARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN...
November 05, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019

IRVING, Texas, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and...
October 14, 2019 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR OCTOBER 15, 2019, AT 8:00...